[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337389-105":59,"doc-detail-337389-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","cx3cr1-is-a-potential-biomarker-of-immune-microenvironment-and-prognosis-in-epithelial-ovarian-cancer","CX3CR1 is a potential biomarker of immune microenvironment and prognosis in epithelial ovarian cancer","","Immunotherapy shows limited efficacy in epithelial ovarian cancer because ideal biomarkers for patient selection remain insufficient. CX3CR1, a chemokine receptor enriched on immune cell membranes and partnered with its ligand CX3CL1, regulates immune-cell chemotaxis and adhesion. A retrospective bioinformatic analysis evaluated CX3CR1 expression, immune associations, and survival impact using multiple public databases, revealing higher CX3CR1 in tumors than normal tissue. Higher CX3CR1 predicted worse overall survival and correlated with infiltration of B cells, CD8+ and CD4+ T cells, macrophages, dendritic cells, and neutrophils, suggesting CX3CR1 shapes the tumor immune microenvironment.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cx3cr1-is-a-potential-biomarker-of-immune-microenvironment-and-prognosis-in-epithelial-ovarian-cancer/337389/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cx3cr1-is-a-potential-biomarker-of-immune-microenvironment-and-prognosis-in-epithelial-ovarian-cancer/337389.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is a biomarker needed for immunotherapy in epithelial ovarian cancer?","Question",{"text":113,"@type":114},"Immunotherapy has limited efficiency in epithelial ovarian cancer, and current prospective trials indicate a lack of ideal biomarkers to identify the best responders.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What did the study find about CX3CR1 expression in cancer versus normal tissue?",{"text":118,"@type":114},"Data from multiple public resources showed CX3CR1 is expressed at higher levels in epithelial ovarian cancer than in normal ovarian tissue.",{"name":120,"@type":111,"acceptedAnswer":121},"How does CX3CR1 relate to patient prognosis?",{"text":122,"@type":114},"Across Gene Expression Profiling Interactive Analysis and Kaplan–Meier plotter datasets, CX3CR1 expression above the median was associated with unfavorable overall survival, and this negative impact was validated by additional databases.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},337389,1790122556,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","®  \n Observational Study   \nCX3CR1 is a potential biomarker of immune microenvironment and prognosis in epithelial ovarian cancer  \nDanfeng Shao, MDa ,* , Honger Zhou, MDa , Huaiying Yu, MDa , Xiaoqing Zhu, MDb  \n\n| Abstract\u003Cbr>Immunotherapy is less efficient for epithelial ovarian cancer and lacks ideal biomarkers to select the best beneficiaries for immunotherapy. CX3CR1 as chemokine receptor mainly expressed on immune cell membranes, and combined with its unique ligand CX3CL1, mediates tissue chemotaxis and adhesion of immune cells. However, the immune functional and prognostic value of CX3CR1 in epithelial ovarian cancer has not been clarified. A comprehensive retrospective analysis was performed by using the online database to identify the underlying immunological mechanisms and prognostic value of CX3CR1 . The Human Protein Atlas, gene expression profiling interactive analysis, and TISIDB (an integrated repository portal for tumor-immune system interactions) database showed that CX3CR1 expressed higher in epithelial ovarian cancer than that in normal ovarian tissue. Four hundred twenty-two cases from Gene Expression Profiling Interactive Analysis and 1656 cases from Kaplan–Meier plotter database showed higher expression of CX3CR1 (above median) was associated with unfavorable overall survival. TIMER, UALCAN, and TISIDB database were applied to validate CX3CR1 negative impact on overall survival. In addition, correlation analysis showed that the expression level of CX3CR1 was positive association with infiltrating levels of B cells (R = 0.31, P = 3. 10e−12), CD8+ T cells (R = 0.26, P = 7.93e−09), CD4+ T cells (R = 0. 11, P = 1.41e−02), macrophages (R = 0.32, P = 4.29e−13), dendritic cells (R = 0.27, P = 2.98e−09), and neutrophil (R = 0.25, P = 3.25e−08) in epithelial ovarian cancer. Therefore, CX3CR1 involved in reshaping the immune microenvironment for epithelial ovarian cancer and maybe a potential immunotherapy target and prognostic marker for ovarian cancer. |\n| --- |\n| Abbreviations: CBioPortal = cBioCancer Genomics Portal , CX3CL1 = CX3C chemokine fractalkine, CX3CR1 = chemokine (C-X3-C motif) receptor 1, DFS = disease-free survival, GEPIA = gene expression profiling interactive analysis, GPCR = G Protein coupled receptor, HPA = Human Protein Atlas, HR = hazards ratio, OS = overall survival (OS), TIMER = Tumor IMmune Estimation Resource database. |\n| Keywords: CX3CR1 , immune, ovarian cancer, prognosis |\n\n1. Introduction  \nOvarian cancer is the most lethal of all gynecological cancers worldwide. In the United States and China, >21,400 and 57,200 women been newly diagnosed with ovarian cancer.[1,2] Due to nonspecific symptoms and the ovary’s location deep within the pelvic cavity, approximately 60% to 70% of ovarian cancer cases are diagnosed at advanced International Federation of Gynecology and Obstetrics stages (III and IV), resulting in delayed diagnoses and treatments. As a result, the 5-year survival rate for stage III and IV cases is 27% and 13%, respectively.[3,4] Ovarian cancer is a heterogeneous tumor with various histological types. Among them, epithelial ovarian cancer accounts for around 90% of all ovarian malignancies.[5] Currently, debulking surgery and chemotherapy containing platinum remain the standard treatment for epithelial ovarian cancer.[6]  \nRecently, numerous studies have suggested that epithelial ovarian cancer is an immunogenic tumor capable of inducing a spontaneous antitumor immune response in the host.[7] Tumorinfiltrating immune cells are present in almost 50% of primary epithelial ovarian cancer tissues, and a high abundance of CD3+ or CD8+ T-cell infiltration is significantly associated with a better prognosis in epithelial ovarian cancer.[8] Immunotherapy, like immune checkpoints inhibitors (like PD-1/PD-L1 and CTLA-4), have been approved to treat solid cancers and some of them have been studied for epithelial ovarian cancer.[9] Prospective clinical trials including KEYNOTE-028, JAVE","cbCaiqjDro5zGxKZ","https://ap.wps.com/l/cbCaiqjDro5zGxKZ","pdf",1802248,"English","# Introduction\n## Epidemiology and clinical challenge in epithelial ovarian cancer\n## Rationale for immunotherapy and biomarker need\n## CX3CR1 biology and study approach","[{\"question\":\"Why is a biomarker needed for immunotherapy in epithelial ovarian cancer?\",\"answer\":\"Immunotherapy has limited efficiency in epithelial ovarian cancer, and current prospective trials indicate a lack of ideal biomarkers to identify the best responders.\"},{\"question\":\"What did the study find about CX3CR1 expression in cancer versus normal tissue?\",\"answer\":\"Data from multiple public resources showed CX3CR1 is expressed at higher levels in epithelial ovarian cancer than in normal ovarian tissue.\"},{\"question\":\"How does CX3CR1 relate to patient prognosis?\",\"answer\":\"Across Gene Expression Profiling Interactive Analysis and Kaplan–Meier plotter datasets, CX3CR1 expression above the median was associated with unfavorable overall survival, and this negative impact was validated by additional databases.\"}]","CX3CR1 is a potential biomarker of immune microenvironment and prognosis in epithelial ovarian cancer | PDF",1790018951,23,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a03d875487495102d91e4ac298bb039.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/783ea7fab47b1f39e846402845beb713.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4821013c10c623410d7ff1a4327ac8f6.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b86391c2306dc702ec36847544a2481.webp",980,1306]